Professor Shi Yuanyuan was invited to visit the Interventional and Cell Therapy Center of Shenzhen H
Recently, Professor Shi Yuanyuan, the founder and chairman of Shenzhen Cell Valley Biomedical Co., Ltd., and Dr. Yang Borui, the executive president of Guangdong Junhou Biomedical, a wholly-owned subsidiary, and Dr. Feng Yaru, the vice president, were invited to visit the Intervention and Cell Therapy Center of Shenzhen Hospital of Peking University. Professor Fan Dayue, the director and consultant of the Center, gave a warm reception.
Chen Junhui, director of the Intervention and Cell Therapy Center of Peking University Shenzhen Hospital, introduced the overall situation of Peking University Shenzhen Hospital and the Intervention and Cell Therapy Center in detail to Chairman Shi Yuanyuan and his party.
At the symposium, Director Chen Junhui first introduced the history and current situation of the center (see introduction). Director Chen introduced in detail the development and operation of the "National Stem Cell Clinical Research Institute" clinical research project, the Phase I Clinical Trial Center of the National Drug Clinical Trial Institute, and the Interventional and Cell Therapy Center in medicine, teaching and research. When referring to the clinical situation and experience summary of cancer patients receiving cell therapy in the center, Director Chen said that it was necessary to focus on the safety of cell therapy. For adverse reactions such as cytokine storms, the clinical team should constantly weigh the risks and benefits of different treatment methods, and strengthen scientific research on early diagnosis of adverse reactions.
Subsequently, Chairman Shi Yuanyuan and Vice President Feng Yaru respectively introduced the development layout and strategic positioning of the South China Cell Factory of Shenzhen Cell Valley, the one-stop cell and gene therapy CRO/CDMO service platform, as well as the production line of anti-virus vectors and the production process of cell products. Chairman Shi Yuanyuan said that Shenzhen Cell Valley has mastered the only clinically industrialized production process of anti-virus vectors in China, which can effectively solve the "technology bottleneck" problem in China's cell gene therapy industry.
Chen Junhui, director of the Intervention and Cell Therapy Center of Peking University Shenzhen Hospital, introduced the overall situation of Peking University Shenzhen Hospital and the Intervention and Cell Therapy Center in detail to Chairman Shi Yuanyuan and his party.
At the symposium, Director Chen Junhui first introduced the history and current situation of the center (see introduction). Director Chen introduced in detail the development and operation of the "National Stem Cell Clinical Research Institute" clinical research project, the Phase I Clinical Trial Center of the National Drug Clinical Trial Institute, and the Interventional and Cell Therapy Center in medicine, teaching and research. When referring to the clinical situation and experience summary of cancer patients receiving cell therapy in the center, Director Chen said that it was necessary to focus on the safety of cell therapy. For adverse reactions such as cytokine storms, the clinical team should constantly weigh the risks and benefits of different treatment methods, and strengthen scientific research on early diagnosis of adverse reactions.
Subsequently, Chairman Shi Yuanyuan and Vice President Feng Yaru respectively introduced the development layout and strategic positioning of the South China Cell Factory of Shenzhen Cell Valley, the one-stop cell and gene therapy CRO/CDMO service platform, as well as the production line of anti-virus vectors and the production process of cell products. Chairman Shi Yuanyuan said that Shenzhen Cell Valley has mastered the only clinically industrialized production process of anti-virus vectors in China, which can effectively solve the "technology bottleneck" problem in China's cell gene therapy industry.
